Home
CRNX
CRNX News

Latest Crinetics Pharmaceuticals Inc. (CRNX) News on June 2, 2025

Crinetics Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2025

GlobeNewswire

10 days ago

Crinetics Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2025

Is There An Opportunity With Crinetics Pharmaceuticals, Inc.'s (NASDAQ:CRNX) 20% Undervaluation?

Simply Wall St.

11 days ago

Is There An Opportunity With Crinetics Pharmaceuticals, Inc.'s (NASDAQ:CRNX) 20% Undervaluation?

Crinetics to Present New Research on Paltusotine, Atumelnant and Unmet Needs in Acromegaly Treatment at the American Association of Clinical Endocrinology Annual Meeting 2025

GlobeNewswire

18 days ago

Crinetics to Present New Research on Paltusotine, Atumelnant and Unmet Needs in Acromegaly Treatment at the American Association of Clinical Endocrinology Annual Meeting 2025

Crinetics Pharmaceuticals Announces May 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

21 days ago

Crinetics Pharmaceuticals Announces May 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Crinetics Pharmaceuticals Inc (CRNX) Q1 2025 Earnings Call Highlights: Strategic Growth and ...

GuruFocus.com

24 days ago

Crinetics Pharmaceuticals Inc (CRNX) Q1 2025 Earnings Call Highlights: Strategic Growth and ...

Is Crinetics Pharmaceuticals, Inc. (CRNX) The Best Stock That Will Bounce Back?

Insider Monkey

24 days ago

Is Crinetics Pharmaceuticals, Inc. (CRNX) The Best Stock That Will Bounce Back?

Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q1 Loss, Tops Revenue Estimates

Zacks

25 days ago

Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q1 Loss, Tops Revenue Estimates

Crinetics Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

GlobeNewswire

25 days ago

Crinetics Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

What To Expect From Crinetics Pharmaceuticals Inc (CRNX) Q1 2025 Earnings

GuruFocus.com

a month ago

What To Expect From Crinetics Pharmaceuticals Inc (CRNX) Q1 2025 Earnings

Crinetics Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025

GlobeNewswire

2 months ago

Crinetics Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025

Crinetics Pharmaceuticals Announces April 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

2 months ago

Crinetics Pharmaceuticals Announces April 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MT Newswires

2 months ago

Crinetics Pharmaceuticals Says EMA Validates Marketing Authorization Application for Acromegaly Drug

Crinetics Pharmaceuticals Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) and Orphan Drug Designation (ODD) for Paltusotine in Acromegaly

GlobeNewswire

2 months ago

Crinetics Pharmaceuticals Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) and Orphan Drug Designation (ODD) for Paltusotine in Acromegaly

MT Newswires

2 months ago

Stifel Initiates Crinetics Pharmaceuticals at Buy With $60 Price Target

Crinetics Pharmaceuticals Announces March 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

3 months ago

Crinetics Pharmaceuticals Announces March 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans

Simply Wall St.

3 months ago

Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans

MT Newswires

3 months ago

Crinetics Pharmaceuticals Q4 Net Loss Narrows

Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

GlobeNewswire

3 months ago

Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Is Crinetics Pharmaceuticals (CRNX) the Worst Performing Mid Cap Stock to Buy According to Analysts?

Insider Monkey

3 months ago

Is Crinetics Pharmaceuticals (CRNX) the Worst Performing Mid Cap Stock to Buy According to Analysts?

What To Expect From Crinetics Pharmaceuticals Inc (CRNX) Q4 2024 Earnings

GuruFocus.com

3 months ago

What To Expect From Crinetics Pharmaceuticals Inc (CRNX) Q4 2024 Earnings

MT Newswires

3 months ago

Crinetics Pharmaceuticals Names Tobin Schilke CFO

Crinetics Pharmaceuticals Appoints Tobin Schilke as Chief Financial Officer

GlobeNewswire

3 months ago

Crinetics Pharmaceuticals Appoints Tobin Schilke as Chief Financial Officer

Crinetics Pharmaceuticals to Participate in Two Upcoming March Investor Conferences

GlobeNewswire

3 months ago

Crinetics Pharmaceuticals to Participate in Two Upcoming March Investor Conferences

MT Newswires

4 months ago

TD Cowen Initiates Crinetics Pharmaceuticals at Buy

Crinetics Pharmaceuticals Announces February 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

4 months ago

Crinetics Pharmaceuticals Announces February 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025

GlobeNewswire

4 months ago

Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025

Crinetics Pharmaceuticals, Inc. (CRNX): One of January’s Biggest Losers

Insider Monkey

4 months ago

Crinetics Pharmaceuticals, Inc. (CRNX): One of January’s Biggest Losers

MT Newswires

4 months ago

Wolfe Research Initiates Coverage on Crinetics Pharmaceuticals With Peer Perform Rating

What Are Analysts Talking About Crinetics Pharmaceuticals (CRNX)?

Insider Monkey

4 months ago

What Are Analysts Talking About Crinetics Pharmaceuticals (CRNX)?

MT Newswires

4 months ago

Jefferies Upgrades Crinetics Pharmaceuticals to Buy From Hold, $55 Price Target

Is Crinetics Pharmaceuticals (CRNX) Among Billionaire Joseph Edelman’s Long-Term Stock Picks?

Insider Monkey

4 months ago

Is Crinetics Pharmaceuticals (CRNX) Among Billionaire Joseph Edelman’s Long-Term Stock Picks?

Crinetics Pharmaceuticals, Inc. (CRNX): The Biotech Stock with Biggest Upside Potential

Insider Monkey

5 months ago

Crinetics Pharmaceuticals, Inc. (CRNX): The Biotech Stock with Biggest Upside Potential

Crinetics Pharmaceuticals Announces January 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

5 months ago

Crinetics Pharmaceuticals Announces January 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MT Newswires

5 months ago

Crinetics Shares Fall After Reporting 'Positive' Phase 2 Results for Congenital Adrenal Hyperplasia Treatment

Crinetics Announces Positive Topline Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH)

GlobeNewswire

5 months ago

Crinetics Announces Positive Topline Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH)

Crinetics Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswire

5 months ago

Crinetics Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Crinetics Pharmaceuticals Appoints Isabel Kalofonos as Chief Commercial Officer

GlobeNewswire

6 months ago

Crinetics Pharmaceuticals Appoints Isabel Kalofonos as Chief Commercial Officer

Crinetics Pharmaceuticals Announces December 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

6 months ago

Crinetics Pharmaceuticals Announces December 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MT Newswires

6 months ago

Crinetics Pharmaceuticals Says US FDA Accepts NDA for Paltusotine to Treat Acromegaly

Crinetics Announces FDA Acceptance of New Drug Application for Paltusotine for Adult Patients with Acromegaly

GlobeNewswire

6 months ago

Crinetics Announces FDA Acceptance of New Drug Application for Paltusotine for Adult Patients with Acromegaly

Crinetics Pharmaceuticals to Participate in Three Upcoming December Investor Conferences

GlobeNewswire

7 months ago

Crinetics Pharmaceuticals to Participate in Three Upcoming December Investor Conferences

UPDATE: Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting

GlobeNewswire

7 months ago

UPDATE: Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting

Crinetics Pharmaceuticals Third Quarter 2024 Earnings: US$0.96 loss per share (vs US$1.01 loss in 3Q 2023)

Simply Wall St.

7 months ago

Crinetics Pharmaceuticals Third Quarter 2024 Earnings: US$0.96 loss per share (vs US$1.01 loss in 3Q 2023)

Crinetics Pharmaceuticals Inc (CRNX) Q3 2024 Earnings Call Highlights: Strategic Advances and ...

GuruFocus.com

7 months ago

Crinetics Pharmaceuticals Inc (CRNX) Q3 2024 Earnings Call Highlights: Strategic Advances and ...

MT Newswires

7 months ago

Crinetics Pharmaceuticals Q3 Net Loss Narrows

Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting

GlobeNewswire

7 months ago

Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting

Crinetics Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire

7 months ago

Crinetics Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

Crinetics Pharmaceuticals Announces November 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

7 months ago

Crinetics Pharmaceuticals Announces November 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Investors might be losing patience for Crinetics Pharmaceuticals' (NASDAQ:CRNX) increasing losses, as stock sheds 5.6% over the past week

Simply Wall St.

7 months ago

Investors might be losing patience for Crinetics Pharmaceuticals' (NASDAQ:CRNX) increasing losses, as stock sheds 5.6% over the past week

State Street Corp's Strategic Acquisition in Crinetics Pharmaceuticals

GuruFocus.com

8 months ago

State Street Corp's Strategic Acquisition in Crinetics Pharmaceuticals

Crinetics Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 12, 2024

GlobeNewswire

8 months ago

Crinetics Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 12, 2024

Crinetics Pharmaceuticals Announces October 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

8 months ago

Crinetics Pharmaceuticals Announces October 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Morning Movers: Arcadium Lithium surges after deal to be acquired

TipRanks

8 months ago

Morning Movers: Arcadium Lithium surges after deal to be acquired

Crinetics Pharmaceuticals Inc (CRNX) Q2 2024 Earnings Call Highlights: Strategic Advances Amid ...

GuruFocus.com

8 months ago

Crinetics Pharmaceuticals Inc (CRNX) Q2 2024 Earnings Call Highlights: Strategic Advances Amid ...

MT Newswires

8 months ago

Update: Crinetics Pharmaceuticals Prices $500 Million Stock Offering

MT Newswires

8 months ago

Crinetics Pharmaceuticals Prices $500 Million Stock Offering

Crinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock

GlobeNewswire

8 months ago

Crinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock

MT Newswires

8 months ago

Crinetics Pharmaceuticals Plans $400 Million Stock Sale

Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock

GlobeNewswire

8 months ago

Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock

MT Newswires

8 months ago

Crinetics Pharmaceuticals Insider Sold Shares Worth $785,306, According to a Recent SEC Filing

MT Newswires

8 months ago

Crinetics Pharmaceuticals Files New Drug Application for Acromegaly Treatment

Crinetics Submits New Drug Application for Paltusotine for the Treatment of Acromegaly

GlobeNewswire

8 months ago

Crinetics Submits New Drug Application for Paltusotine for the Treatment of Acromegaly

Insider Sale: Chief Scientific Officer Stephen Betz Sells Shares of Crinetics Pharmaceuticals ...

GuruFocus.com

9 months ago

Insider Sale: Chief Scientific Officer Stephen Betz Sells Shares of Crinetics Pharmaceuticals ...

Crinetics Pharmaceuticals Announces September 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

9 months ago

Crinetics Pharmaceuticals Announces September 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Crinetics Pharmaceuticals, Inc. (CRNX): Among the Best Mid-Cap Healthcare Stocks To Buy Now

Insider Monkey

9 months ago

Crinetics Pharmaceuticals, Inc. (CRNX): Among the Best Mid-Cap Healthcare Stocks To Buy Now

Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences

GlobeNewswire

9 months ago

Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences

Insider Sale: Chief Scientific Officer Stephen Betz Sells 3,000 Shares of Crinetics ...

GuruFocus.com

9 months ago

Insider Sale: Chief Scientific Officer Stephen Betz Sells 3,000 Shares of Crinetics ...

Insider Sale: Chief Scientific Officer Stephen Betz Sells 3,000 Shares of Crinetics ...

GuruFocus.com

10 months ago

Insider Sale: Chief Scientific Officer Stephen Betz Sells 3,000 Shares of Crinetics ...

Crinetics Pharmaceuticals Announces August 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

10 months ago

Crinetics Pharmaceuticals Announces August 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

We Think Crinetics Pharmaceuticals (NASDAQ:CRNX) Can Afford To Drive Business Growth

Simply Wall St.

10 months ago

We Think Crinetics Pharmaceuticals (NASDAQ:CRNX) Can Afford To Drive Business Growth

MT Newswires

10 months ago

Oppenheimer Trims Crinetics Pharmaceuticals Price Target to $73 From $74, Maintains Outperform Rating

Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q2 Loss, Misses Revenue Estimates

Zacks

10 months ago

Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q2 Loss, Misses Revenue Estimates

Crinetics Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire

10 months ago

Crinetics Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

Crinetics Launches ACRO/TRUTH Educational Initiative to Raise Awareness of Acromegaly Treatment Challenges

GlobeNewswire

10 months ago

Crinetics Launches ACRO/TRUTH Educational Initiative to Raise Awareness of Acromegaly Treatment Challenges

Earnings Preview: Zevra Therapeutics (ZVRA) Q2 Earnings Expected to Decline

Zacks

10 months ago

Earnings Preview: Zevra Therapeutics (ZVRA) Q2 Earnings Expected to Decline

Crinetics Pharmaceuticals, Inc. (CRNX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Zacks

10 months ago

Crinetics Pharmaceuticals, Inc. (CRNX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Insider Sale: Chief Scientific Officer Stephen Betz Sells Shares of Crinetics Pharmaceuticals ...

GuruFocus.com

10 months ago

Insider Sale: Chief Scientific Officer Stephen Betz Sells Shares of Crinetics Pharmaceuticals ...

Crinetics Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 8, 2024

GlobeNewswire

10 months ago

Crinetics Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 8, 2024

MT Newswires

a year ago

Crinetics Pharmaceuticals Insider Sold Shares Worth $1,485,000, According to a Recent SEC Filing

Insider Sale: Chief Scientific Officer Stephen Betz Sells Shares of Crinetics Pharmaceuticals ...

GuruFocus.com

a year ago

Insider Sale: Chief Scientific Officer Stephen Betz Sells Shares of Crinetics Pharmaceuticals ...

Crinetics Pharmaceuticals Announces July 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

a year ago

Crinetics Pharmaceuticals Announces July 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MT Newswires

a year ago

JPMorgan Raises Price Target on Crinetics Pharmaceuticals to $54 From $47, Maintains Overweight Rating

Insider Sale: Chief Scientific Officer Stephen Betz Sells Shares of Crinetics Pharmaceuticals ...

GuruFocus.com

a year ago

Insider Sale: Chief Scientific Officer Stephen Betz Sells Shares of Crinetics Pharmaceuticals ...

MT Newswires

a year ago

Crinetics Pharmaceuticals Insider Sold Shares Worth $434,435, According to a Recent SEC Filing

EY Announces Scott Struthers, Ph.D., CEO and Founder of Crinetics Pharmaceuticals, as an Entrepreneur Of The Year® 2024 Pacific Southwest Award Winner

GlobeNewswire

a year ago

EY Announces Scott Struthers, Ph.D., CEO and Founder of Crinetics Pharmaceuticals, as an Entrepreneur Of The Year® 2024 Pacific Southwest Award Winner

Insider Sale at Crinetics Pharmaceuticals Inc (CRNX): Chief Scientific Officer Stephen Betz ...

GuruFocus.com

a year ago

Insider Sale at Crinetics Pharmaceuticals Inc (CRNX): Chief Scientific Officer Stephen Betz ...

Crinetics Pharmaceuticals Announces June 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

a year ago

Crinetics Pharmaceuticals Announces June 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Engelhart Commodities Trading Partners Agrees to Acquire Trailstone, Strengthening Commitment to the Energy Transition

Business Wire

a year ago

Engelhart Commodities Trading Partners Agrees to Acquire Trailstone, Strengthening Commitment to the Energy Transition

Delfi Meedia, a subsidiary of AS Ekspress Grupp to acquire business operations of Eesti Koolitus- ja Konverentsikeskus

GlobeNewswire

a year ago

Delfi Meedia, a subsidiary of AS Ekspress Grupp to acquire business operations of Eesti Koolitus- ja Konverentsikeskus

Share buy-back programme - week 23

GlobeNewswire

a year ago

Share buy-back programme - week 23

Do Scientex Berhad's (KLSE:SCIENTX) Earnings Warrant Your Attention?

Simply Wall St.

a year ago

Do Scientex Berhad's (KLSE:SCIENTX) Earnings Warrant Your Attention?

Japan's service sector mood hits nearly 2-year low in May

Reuters

a year ago

Japan's service sector mood hits nearly 2-year low in May

N. Korea sends more balloons as Kim's sister warns of 'new counteraction'

AFP

a year ago

N. Korea sends more balloons as Kim's sister warns of 'new counteraction'

Enduring role of 'treasuring the past' hailed

PR Newswire

a year ago

Enduring role of 'treasuring the past' hailed

Velcan Holdings: buyback offer of 500 000 shares at Eur 14.5 per share

GlobeNewswire

a year ago

Velcan Holdings: buyback offer of 500 000 shares at Eur 14.5 per share

MT Newswires

a year ago

Oppenheimer Raises Price Target on Crinetics Pharmaceuticals to $74 From $55, Maintains Outperform Rating

Crinetics Unveils 'Stunning' Results In Highly Anticipated Study

Investor's Business Daily

a year ago

Crinetics Unveils 'Stunning' Results In Highly Anticipated Study

Crinetics Announces Positive Initial Findings at ENDO 2024 for Atumelnant in Two Ongoing, Open-Label Studies for the Treatment of Congenital Adrenal Hyperplasia (CAH) and ACTH-Dependent Cushing’s Syndrome (ADCS)

GlobeNewswire

a year ago

Crinetics Announces Positive Initial Findings at ENDO 2024 for Atumelnant in Two Ongoing, Open-Label Studies for the Treatment of Congenital Adrenal Hyperplasia (CAH) and ACTH-Dependent Cushing’s Syndrome (ADCS)

Crinetics Presents New Data at ENDO 2024 that Increases Body of Evidence Positioning Once-Daily, Oral Paltusotine as Potential First-Choice Treatment Option for Acromegaly

GlobeNewswire

a year ago

Crinetics Presents New Data at ENDO 2024 that Increases Body of Evidence Positioning Once-Daily, Oral Paltusotine as Potential First-Choice Treatment Option for Acromegaly

Shareholders Will Probably Not Have Any Issues With Crinetics Pharmaceuticals, Inc.'s (NASDAQ:CRNX) CEO Compensation

Simply Wall St.

a year ago

Shareholders Will Probably Not Have Any Issues With Crinetics Pharmaceuticals, Inc.'s (NASDAQ:CRNX) CEO Compensation

Share on Social Networks: